Replies to post #19074 on BioCurex, Inc.(fka BOCX)

[Gold Seeker]

The bocx, I have stated that RECAF could probably get approved to monitor colon cancer. I did not say if could get approved to monitor any other type of cancer. DR70, after a period of several years and supporting clinical trials, did obtain FDA approval to monitor colon cancer. So far, and it has been almost a year since approval, NO company has stepped forward to license the test. Why do you think RECAF will fare any better? I really have no expert opinion of how RECAF would be received by the medical communitiy but other universal markers have not been successful. That is the basis of my opinion.

Why do you think that Inverness has not given any indication of progress 17 months after the effective date of the agreement? Could a potential investor for a placement sign a non disclosure agreement and see the quarterly updates for Inverness?

[Gold Seeker]

The bocx, I was just reading the press release posted today about the ovarian cancer markers.

"Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in-vitro diagnostic products for the management of human disease states, with an emphasis in oncology. Fujirebio Diagnostics is one of the group companies of Miraca Holdings, Inc., in Japan, set up in July 2005 to combine Fujirebio Inc., the leading in-vitro diagnostics company, and SRL, Inc., the top provider of clinical laboratory testing services in Japan"

SRL was the company that licensed the universal marker HAAH back in 2003 and were forecasting revenue from the test of $700K within 3 years. Six years later, I can no longer find any reference to the HAAH marker in their product line or pipeline. Maybe Fujirebio axed the program.

[Gold Seeker]

As for getting markers approved for monitoring, I think a lot of companies have come to the conclusion that the FDA is going to be reluctant to create another mess like PSA with all the false positives. It is a fact that doctors are using some tests approved for monitoring and using them for diagnosis. Not screening but diagnosis.